A Canadian Open-Label, Multicenter, Expanded Access Study of Oral Nilotinib in Adult Patients With Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase.

Trial Profile

A Canadian Open-Label, Multicenter, Expanded Access Study of Oral Nilotinib in Adult Patients With Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 12 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 06 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top